ORIGINAL RESEARCH article
Front. Oncol.
Sec. Genitourinary Oncology
This article is part of the Research TopicNovel Therapeutics in Genitourinary (GU) OncologyView all articles
Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette–Guerin in intermediate-and high-risk non-muscle-invasive bladder cancer
Provisionally accepted
- Xingtai People's Hospital, Xingtai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The recurrence rate remains high in patients with intermediate-and high-risk non-muscle-invasive bladder cancer (NMIBC), and some patients may experience disease progression despite curative trans-urethral resection and adjuvant therapy. Objective: To compare the outcomes of intermediate-and high-risk NMIBC patients treated with Bacillus Calmette–Guerin (BCG) versus hyperthermic intravesical chemotherapy (HIVEC) with gemcitabine (GEM). Methods: A retrospective analysis of our single-institutional, prospectively collected database from July 2018 to February 2020 was performed. Patients with intermediate-and high-risk NMIBC and treated with HIVEC/GEM or BCG were selected. The two adjuvant therapies were compared in terms of recurrence-free survival (RFS), progress-free survival (PFS), and cancer-specific survival (CSS) at 24 months. Adverse events were also assessed and compared between groups. Results: A total of 85 patients (38 in the HIVEC/GEM group and 47 in the BCG group) were included in the study. Patients' characteristics were comparable between groups. There were no statistically significant differences in RFS (78.0% for HIVEC/GEM versus 75.0% for BCG, p = 0.592), PFS (91.7% for HIVEC/GEM versus 94.6% for BCG, p = 0.670), and CSS at 24 months. AEs were less common with HIVEC/GEM treatment than BCG (47.37% (18/38) versus 70.20% (33/47), p = 0.033). Most AEs were mild with CTCAE grade 1-2 (42.1% (16/38) for HIVEC/GEM and 63.8% (30/47) for BCG, p = 0.046). Conclusions: Among patients with intermediate-and high-risk NMIBC, hyperthermic intravesical chemotherapy combined with gemcitabine, compared with BCG treatment, significantly reduced the adverse events rate without compromising oncological survival outcomes. The primary limitations of this study are its small sample size and retrospective nature.
Keywords: Bladder cancer, hyperthermic intravesical chemotherapy, gemcitabine, Bacillus Calmette–Guerin, hyperthermia
Received: 29 Sep 2025; Accepted: 08 Dec 2025.
Copyright: © 2025 Yan, Hu, Li, Feng, Zhu, Xu, Chen and Qiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bing Yan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.